Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Refractory or Relapsed Solid Tumors 1

Interventions

pembrolizumab 7Specimen Handling 7tislelizumab 6Cisplatin 6Carboplatin 6atezolizumab 5Pemetrexed 5Bevacizumab 5Platinum 4Interviews as Topic 4Injections 4Educational Status 4Cyclophosphamide 4Biopsy 4fludarabine 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Early Intervention, Educational 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2X-Rays 2Trastuzumab 2Standard of Care 2Radiotherapy 2Radiation 2Practice Guidelines as Topic 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Itraconazole × Other solid neoplasm × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡